Abstract
The clinical application of tyrosine kinase inhibitors for cancer treatment represents a therapeutic breakthrough. The rationale for development of these compounds rests on the observation that tyrosine kinases are central components of the cellular signaling apparatus and are deregulated in many human malignancies. Successful tyrosine kinase inhibitors target aberrant pathways that are critical for tumor cell viability. Herein, we will review the current state-of-the-art using imatinib mesylate (Gleevec™, Glivec®, CGP57148, formerly STI571; Novartis Pharmaceuticals) as it is used in the treatment of gastrointestinal stromal tumors (GISTs). GISTs, the most common mesenchymal tumors of the gastrointestinal tract, originate from the neoplastic transformation of the intestinal pacemaker cell, the interstitial cell of Cajal. GISTs commonly have mutations in the kit gene, resulting in a gain-of-function mutation and ligand-independent constitutive activation of the Kit receptor tyrosine kinase. The use of imatinib has greatly increased the therapeutic efficacy for this otherwise chemotherapy-resistant tumor. Resistance to the drug is the major cause of treatment failure, emphasizing the need for researchers to understand Kit signaling pathways so as to identify new therapeutic targets. This article will review the development, pharmacology, and clinical trials of imatinib in the setting of GIST. The potential role of imatinib in the postoperative and preoperative setting will be discussed.
Keywords: kit, gastrointestinal stromal tumor, imatinib mesylate, sarcoma, targeted therapy, clinical trial
Current Cancer Therapy Reviews
Title: Imatinib Mesylate: Targeted Therapy of Gastrointestinal Stromal Tumor
Volume: 1 Issue: 1
Author(s): Jonathan C. Trent, Jheri Dupart and Wei Zhang
Affiliation:
Keywords: kit, gastrointestinal stromal tumor, imatinib mesylate, sarcoma, targeted therapy, clinical trial
Abstract: The clinical application of tyrosine kinase inhibitors for cancer treatment represents a therapeutic breakthrough. The rationale for development of these compounds rests on the observation that tyrosine kinases are central components of the cellular signaling apparatus and are deregulated in many human malignancies. Successful tyrosine kinase inhibitors target aberrant pathways that are critical for tumor cell viability. Herein, we will review the current state-of-the-art using imatinib mesylate (Gleevec™, Glivec®, CGP57148, formerly STI571; Novartis Pharmaceuticals) as it is used in the treatment of gastrointestinal stromal tumors (GISTs). GISTs, the most common mesenchymal tumors of the gastrointestinal tract, originate from the neoplastic transformation of the intestinal pacemaker cell, the interstitial cell of Cajal. GISTs commonly have mutations in the kit gene, resulting in a gain-of-function mutation and ligand-independent constitutive activation of the Kit receptor tyrosine kinase. The use of imatinib has greatly increased the therapeutic efficacy for this otherwise chemotherapy-resistant tumor. Resistance to the drug is the major cause of treatment failure, emphasizing the need for researchers to understand Kit signaling pathways so as to identify new therapeutic targets. This article will review the development, pharmacology, and clinical trials of imatinib in the setting of GIST. The potential role of imatinib in the postoperative and preoperative setting will be discussed.
Export Options
About this article
Cite this article as:
Trent C. Jonathan, Dupart Jheri and Zhang Wei, Imatinib Mesylate: Targeted Therapy of Gastrointestinal Stromal Tumor, Current Cancer Therapy Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573394052952465
DOI https://dx.doi.org/10.2174/1573394052952465 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Advancements in Lipid Nanoparticle Delivery Systems for mRNA Therapeutics
The thematic issue will focus on key areas such as lipid nanoparticles, mRNA therapeutics, drug delivery systems, nanotechnology in medicine, targeted therapy, non-viral vectors, precision medicine, and biomedical engineering.read more
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
SAR, QSAR and Docking of Anticancer Flavonoids and Variants: A Review
Current Topics in Medicinal Chemistry Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets Detection of VEGF165 Using an Aptamer Affinity Probe in Microchip Capillary Electrophoresis
Current Pharmaceutical Analysis Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging Capsid (CA) Protein as a Novel Drug Target: Recent Progress in the Research of HIV-1 CA Inhibitors
Mini-Reviews in Medicinal Chemistry The Signal Pathway of Antibiotic Alternatives on Intestinal Microbiota and Immune Function
Current Protein & Peptide Science Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery Double-Faced Role of Human Mesenchymal Stem Cells and their Role/Challenges in Cancer Therapy
Current Stem Cell Research & Therapy Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
Current Medicinal Chemistry ChemoImmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents
Current Medicinal Chemistry Selective Activation of Intracellular Signalling Pathways in Dendritic Cells for Cancer Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery Editorial [Hot Topic:Therapeutic Potential of Peptide Motifs - Part V (Executive Guest Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Hepatocellular Carcinoma Detection by Gallium Scan and Subsequent Treatment by Gallium Maltolate: Rationale and Case Study
Anti-Cancer Agents in Medicinal Chemistry An Analysis of Structure-function Co-relation between GLI Oncoprotein and HLA Immune-gene Transcriptional Regulation through Molecular Docking
Current Cancer Therapy Reviews Medicinal Chemistry and Pharmacological Effects of Farnesoid X Receptor (FXR) Antagonists
Current Topics in Medicinal Chemistry Tetrandrine for Targeting Therapy Resistance in Cancer
Current Topics in Medicinal Chemistry Laboratory Techniques for Human Viral Encephalitis Diagnosis
Infectious Disorders - Drug Targets